# US 2008/0306431 A1 · Methods of reducing surgical complications in cancer patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306431 A1
- Document ID: US20080306431A1
- Status: Published application
- Kind: A1
- Application number: 12/118,167
- Filed: 2008-05-09
- Published: 2008-12-11
- Earliest claimed: 2007-05-11
- Assignees: Biomet Biologics, LLC
- Inventors: John Yoo
- Web page: https://patentgrep.com/patent/US20080306431A1

## CPC

- A61M 1/3693: {using separation based on different densities of components, e.g. centrifuging}
- A61B 17/00491: {Surgical glue applicators}
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61B 2017/00495: {for two-component glue}
- A61M 5/19: having more than one chamber
- A61M 2202/0415: Plasma
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

A method of treating irradiated tissue, such as for revascularizing and preventing or reducing wound healing complications in a human or other animal subject having cancer. The method comprises administering to the irradiated tissue a therapeutic composition comprising one or more of platelet rich plasma, platelet poor plasma or platelet concentrate. In some embodiments the complications sought to be prevented and/or reduced can include: fibrotic tissue, prolonged would drainage, hematomas, seromas, fistula formation infection, pain, poor coloration, deficient vascularity, and desensitization in or around the irradiated site.

## Claims

### Claim 1

A method for treating irradiated tissue in a human or other animal subject, the method comprising:
identifying cancerous tissue in the subject;
irradiating tissue comprising the cancerous tissue, forming irradiated tissue in the subject;
waiting for a period of time after the irradiating; and
administering a blood component to the irradiated tissue after the waiting period.

### Claim 2 (depends on 1)

The method according to claim 1, further comprising surgical intervention to remove the cancerous tissue.

### Claim 3 (depends on 2)

A method according to claim 2, wherein the surgical intervention is performed prior to the irradiating.

### Claim 4 (depends on 2)

A method according to claim 2, wherein the surgical intervention is performed after the irradiating.

### Claim 5 (depends on 1)

A method according to claim 1, wherein the cancerous tissue is in the head or neck.

### Claim 6 (depends on 5)

A method according to claim 5, wherein the cancerous tissue site is in the neck and the method further comprises a neck dissection performed after the irradiating, and the neck dissection is selected from the group consisting of salvage neck dissection, radical neck dissection, dissection of the oropharynx, salvage neck dissection, modified radical neck dissection, extended radical neck dissection, elective neck dissections, supraomohyoid neck dissection, anterior compartment neck dissection, posterolateral neck dissection, lateral neck dissection.

### Claim 7 (depends on 5)

A method according to claim 5, wherein the cancerous tissue is in the head and the method further comprises a head dissection of the tissue.

### Claim 8 (depends on 1)

A method according to claim 1, wherein the cancerous tissue is in a breast.

### Claim 9 (depends on 1)

A method according to claim 1, wherein the irradiating is performed with two or more doses of radiation administered to the tumor site within a period of 3 months or less.

### Claim 10 (depends on 1)

A method according to claim 1, wherein the blood component is administered in an amount sufficient to reduce one or more complications comprising prolonged wound drainage, hematomas, seromas, fistula formation, infection, pain, fibrotic growth, poor coloration, and desensitization.

### Claim 11 (depends on 1)

A method according to claim 1, wherein the blood component is administered in an amount effective to increase vascularization of the irradiated tissue.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the blood component is administered in an amount effective to reduce fibrotic growth in the irradiated tissue.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the administering comprises administering the blood component to irradiated tissue proximate to the site of the cancerous tissue

### Claim 14 (depends on 1)

A method according to claim 1, wherein the blood component comprises platelet rich plasma, platelet poor plasma, and platelet poor plasma concentrate.

### Claim 15 (depends on 1)

The method according to claim 1 further comprising:
a. obtaining blood compatible with the subject;
b. fractionating the blood to produce the blood component, wherein the blood component comprises consisting of platelet rich plasma and platelet poor plasma.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the fractionating comprises centrifuging the blood in a container including a buoy that is able to separate the blood into two or more fractions having different densities.

### Claim 17 (depends on 1)

The method according to claim 1, further comprising administering to the irradiated tissue an optional material selected from the group consisting of platelet activators, scaffolds, bioactive materials, cytokines, and combinations thereof.

### Claim 18 (depends on 17)

The method according to claim 17 wherein the platelet activator is selected from the group consisting of thrombin, autologous thrombin, CaCl2, a coagulation factor, or combinations thereof.

### Claim 19 (depends on 17)

A method according to claim 17 comprising administering an antineoplastic agent to the subject.

### Claim 20 (depends on 1)

A method according to claim 1, wherein the period of time is from about 1 month to about 7 months.

### Claim 21

A method for treating a malignant tumor in the head or neck of a human or animal subject, comprising the steps of:
identifying the site of the tumor in the head or neck tissue;
irradiating the site;
removing tissue from the site; and
administering a blood component to the irradiated site at a time from about 1 month to about 7 months after irradiating the site.

### Claim 22 (depends on 21)

A method according to claim 21, wherein the blood component is administered in an amount effective to increase vascularization of tissue at the irradiated site.

### Claim 23 (depends on 21)

The method according to claim 21, wherein the blood component is administered in an amount effective to reduce fibrotic growth at the tissue site.

### Claim 24

A method for treating a malignant breast tumor in a breast of a human or animal subject, comprising the steps of:
identifying the site of the breast tumor;
removing tissue from the site;
irradiating the site; and
administering a blood component to the irradiated site at a time from about 1 month to about 5 months after irradiating the site.

### Claim 25 (depends on 24)

A method according to claim 24, wherein the blood component is administered in an amount effective to increase vascularization of tissue at the irradiated site.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the blood component is administered in an amount effective to reduce fibrotic growth at the irradiated site.
